AVAC
Global Advocacy for HIV Prevention

Preventive HIV Vaccine Trials, April 2013

Protocol Number	Sponsor	Phase	Vaccine Regimen	Strategy	Start Date	Status/ Estimated Completion	Population	Number	Country
Phase IIb (safety and efficacy)									
HVTN 505	HVTN	IIb	DNA plasmid rAd5	DNA (conventional delivery) Adenovirus (human)	May 2009	Ongoing *Immunizations stopped early due to non-efficacy; participant follow-up continues.*	MSM	2500	US
Phase II (safety, adherence, acceptability, feasibility)									
RV305	MHRP	II	ALVAC-HIV vCP1521 AIDSVAX B/E	Poxvirus (canarypox) Protein (gp120)	March 2012	Ongoing/ June 2013	Men/women	162	Thailand
TaMoVac II	MHRP	II	HIVIS DNA MVA-CMDR	DNA (conventional delivery) Poxvirus (MVA)	November 2012	Ongoing/ January 2015	Men/women	198	Mozambique, Tanzania
ANRS 149 LIGHT	ANRS	II	GTU-Multi HIV B HIV-LIPO-5	DNA (conventional delivery) Lipopeptide	May 2013	Planned/ December 2015	Men/women	105	France
NCAIDS/ China X111012202	NCAID	II	rTV DNA	Virosome-based DNA (conventional delivery)	August 2012	Ongoing/ April 2014	Men/women	150	China
Russian Federation	Russia	II	VICHREPOL	Protein (other)	Not available	Pending/Not available	Not available		Russia
Phase Ib and I/II (safety, adherence, acceptability, feasibility)									
HVTN 076	HVTN	Ib	DNA plasmid rAd5	DNA (conventional delivery) Adenovirus (human)	September 2011	Ongoing/ August 2013	Men/women	45	US
HVTN 085	HVTN	Ib	rAd5 gag-pol/env ABC	Adenovirus (human)	February 2012	Ongoing/ December 2013	Men/women	90	US
HVTN 078	HVTN	Ib	NYVAC-B rAd5	Poxvirus (NYVAC) Adenovirus (human)	October 2009	Participants in follow-up	Men/women	80	Switzerland
HVTN 077	HVTN	Ib	rAd35/rAd5 env A DNA	Adenovirus (human) DNA (conventional delivery)	February 2009	Participants in follow-up	Men/women	192	US
HVTN 082	HVTN	Ib	rAd5 DNA plasmid	Adenovirus (human) DNA (conventional delivery)	June 2010	Participants in follow-up	Men/women	8	US
HVTN 084	HVTN	Ib	rAD5 gal-pol/env ABC	Adenovirus (human)	March 2011	Participants in follow-up	Men/women	100	US, Brazil, Peru, Switzerland

Phase I (safety, adherence, acceptability, feasibility)									
HVTN 094	HVTN	I	GEO-D03 plasmid DNA MVA62B	DNA (conventional delivery) Poxvirus (MVA)	May 2012	Ongoing/ February 2014	Men/women	48	US
HVTN 087	HVTN	I	HIV-MAG pDNA HIV-1 rVSV gag IL-12 pDNA	DNA (alternative delivery) Vesicular stomatitis virus DNA (conventional delivery)	May 2012	Ongoing/ February 2014	Men/women	100	US
HVTN 073E/ SAAVI102	HVTN, SAAVI	I	Novartis Sub C gp140 MF59C.1	Protein (gp140) Other (adjuvant)	October 2011	Participants in follow-up	Men/women	48	US, South Africa
HVTN 086/ SAAVI 103	HVTN, SAAVI	I	Novartis Sub C gp140 MF59C.1 SAAVI DNA-C2 SAAVI MVA-C	Protein (gp140) Other (adjuvant) DNA (conventional delivery) Poxvirus (MVA)	December 2011	Ongoing/ December 2013	Men/women	184	South Africa
HVTN 092	HVTN	I	DNA-HIV-PT123 NYVAC-HIV PT1 NYVAC-HIV PT-4	DNA (conventional delivery) Poxvirus (NYVAC)	May 2013	Planned/ September 2014	Men/women	204	US
HVTN 088	HVTN	I	Novartis Sub C gp140 MF59C.1	Protein (gp140) Other (adjuvant)	July 2011	Participants in follow-up	Men/women	40	US
HVTN 096	HVTN	I	DNA-HIV-PT123 NYVAC-HIV PT1 NYVAC-HIV PT-4 AIDSVAX B/E	DNA (conventional delivery) Poxvirus (NYVAC) Protein (gp120)	August 2012	Ongoing/ August 2014	Men/women	96	Switzerland
ISS P-002	Istituto Superiore di Sanita	I	Tat protein HIV-1 delta-V2 Env	DNA (conventional delivery) HIV-1	September 2011	Ongoing/ February 2014	Men/women	50	Italy
SSC-0710	Rockefeller	I	DCVax001 + PolyICLC	Protein (other)	May 2010	Ongoing/ May 2013	Men/women	45	US
IAVI S001	IAVI	I	Sendai SeV-G(NP) Ad35.ENVA	Sendai virus Adenovirus (human)	March 2013	Ongoing/ March 2014	Men/women	64	Kenya, Rwanda, UK
HIV-CORE 002	University of Oxford	I	ChAdV63.HIVconsv MVA.HIVconv pSG2.HIVconsvDNA	Adenovirus (chimp) Poxvirus (MVA) DNA (conventional delivery)	October 2010	Complete/ October 2012	Men/women	32	UK

GSK 732462 *(Long-term follow-up)*	GSK	I	GSK Protein	Protein (gp120)	March 2010	Ongoing/ December 2017	Men/women	213	US, France, Germany, Spain
EuroNeut41	EC	I	(nasal) EN41-FPA2 (gp41) (IM) EN41-FPA2 (gp41)	Protein (other)	January 2012	Participants in follow-up	Women	48	UK
HVTN 083	HVTN	I	rAD35 env A rAd5 env A rAd env B	Adenovirus (human)	October 2010	Participants in follow-up	Men/women	180	US
HVTN 090	HVTN	I	VSV Indiana HIV gag	Vesicular stomatitis virus	October 2011	Participants in follow-up	Men/women	60	US
RV 262	MHRP	I	PENNVAX-G DNA MVA-CMDR	DNA (alternative delivery) Poxvirus (MVA)	February 2010	Ongoing/ December 2013	Men/women	92	US, Kenya, Tanzania, Uganda
IAVI B004	IAVI	I	HIV-MAG pDNA Ad35-GRIN/env IL-12 pDNA	DNA (alternative delivery) Adenovirus (human) DNA (conventional delivery)	December 2011	Ongoing/ April 2013	Men/women	75	Kenya, Rwanda, Uganda
TaMoVac01-MZ	EDCTP	I	HIVIS DNA MVA CMDR	DNA (conventional delivery) Poxvirus (MVA)	August 2011	Complete/ March 2013	Men/women	24	Mozambique
GV-TH-01	GeoVax	I	JS7 plasmid DNA MVA62B	DNA (conventional delivery) Poxvirus (MVA)	June 2010	Ongoing/ May 2014	Men/women	10	US
07-I-0167	NIAID	I	rAd35 rAd5 env A	Adenovirus (human)	May 2007	Ongoing/ Not available	Men/women	35	US
IPCAVD 003	NIAID	I	Ad26.ENVA01	Adenovirus (human)	September 2010	Complete/ November 2012	Men/Women	24	US
IPCAVD 002	NIAID	I	Ad5.ENVA.48 HIV-1	Adenovirus (human)	February 2009	Complete/ December 2012	Men/Women	48	US
IPCAVD 004/ IAVI B003/ HVTN 091	NIAID, IAVI, HVTN, Ragon Institute	I	Ad26.ENVA.0 Ad35-ENV	Adenovirus (human)	October 2010	Ongoing/ November 2013	Men/women	80	Kenya, Rwanda, South Africa, US